ProfileGDS5678 / 1426343_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 83% 83% 80% 82% 84% 83% 82% 83% 84% 83% 82% 81% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0622683
GSM967853U87-EV human glioblastoma xenograft - Control 26.1903883
GSM967854U87-EV human glioblastoma xenograft - Control 36.0207683
GSM967855U87-EV human glioblastoma xenograft - Control 45.7964880
GSM967856U87-EV human glioblastoma xenograft - Control 56.0210682
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0629484
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9657683
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9549482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0693783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2305284
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0135883
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.056682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8473381
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2151584